FMCQF
Fresenius Medical Care AG
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
43.01
▼ 8.43 (16.39%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
51.44
Day high
43.08
Day low
43.01
Volume
2.00K
Market cap
$11.45B
P/E (TTM)
11.11
52W range
42.00 – 56.24
Trailing performance
Returnvs SPY
1W
0.00%
+1.1%
1M
+5.30%
+1.9%
3M
+22.48%
+20.0%
6M
+4.53%
-7.4%
YTD
+10.58%
-1.5%
1Y
+0.86%
-19.3%
3Y
+3.25%
-71.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FMCQF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
76.11M
Total on file
Fundamentals
Market cap$11.45B
Enterprise value$24.58B
Revenue (TTM)$19.43B
Gross profit$5.12B
EBITDA$2.72B
Net income$937.78M
EPS (TTM)$3.87
Free cash flow$2.02B
Total cash$1.06B
Total debt$10.98B
Book value / share$54.62
Shares outstanding266.11M
Float181.89M
Short % of float—
Dividend yield3.37%
Beta (5Y)0.84
Valuation & profitability ratios
Trailing P/E11.11
Forward P/E—
PEG ratio0.90
Price / sales—
Price / book0.79
EV / revenue1.27
EV / EBITDA9.03
Gross margin26.35%
Operating margin10.77%
Profit margin4.83%
Return on equity8.52%
Return on assets3.98%
Debt / equity81.13
Current ratio1.07
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $19.63B | $19.34B | $19.45B | $19.40B | +1.5% |
| Operating revenue | $19.63B | $19.34B | $19.45B | $19.40B | +1.5% |
| Cost of revenue | $14.60B | $14.58B | $14.53B | $14.50B | +0.1% |
| Gross profit | $5.03B | $4.76B | $4.93B | $4.89B | +5.7% |
| Research & development | $157.97M | $183.49M | $231.97M | $228.62M | -13.9% |
| Selling, general & admin | $3.03B | $3.14B | $3.20B | $3.17B | -3.5% |
| Total operating expense | $3.20B | $3.29B | $3.45B | $3.44B | -2.7% |
| Operating income | $1.83B | $1.47B | $1.48B | $1.45B | +24.5% |
| Net interest income | -$314.80M | -$335.47M | -$336.42M | -$292.48M | +6.2% |
| Pre-tax income | $1.51B | $1.06B | $1.03B | $1.22B | +43.1% |
| Tax provision | $320.97M | $316.06M | $300.56M | $324.95M | +1.6% |
| Net income | $978.37M | $537.91M | $499.00M | $673.40M | +81.9% |
| Net income to common | $978.37M | $537.91M | $499.00M | $673.40M | +81.9% |
| Basic EPS | 3.36 | 1.83 | 1.70 | 2.30 | +83.6% |
| Diluted EPS | 3.36 | 1.83 | 1.70 | 2.30 | +83.6% |
| EBIT | $1.90B | $1.46B | $1.46B | $1.58B | +29.6% |
| EBITDA | $3.40B | $3.21B | $3.21B | $3.42B | +6.0% |
| Basic shares | 291.19M | 293.41M | 293.41M | 293.25M | -0.8% |
| Diluted shares | 291.19M | 293.41M | 293.41M | 293.25M | -0.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.58B | $1.15B | $1.38B | $1.27B | +37.5% |
| Cash & short-term investments | $1.82B | $1.45B | $1.51B | $1.43B | +25.9% |
| Accounts receivable | $3.16B | $3.40B | $3.43B | $3.67B | -6.9% |
| Inventory | $2.14B | $2.07B | $2.18B | $2.30B | +3.5% |
| Total current assets | $7.90B | $7.92B | $8.70B | $8.20B | -0.3% |
| Property, plant & equipment | $6.50B | $7.26B | $7.45B | $8.34B | -10.5% |
| Goodwill & intangibles | $14.83B | $16.54B | $16.01B | $17.31B | -10.4% |
| Total assets | $31.00B | $33.57B | $33.93B | $35.75B | -7.6% |
| Total current liabilities | $6.25B | $5.66B | $6.11B | $6.47B | +10.3% |
| Current debt | $1.61B | $577.38M | $944.60M | $1.34B | +179.4% |
| Long-term debt | $5.69B | $6.26B | $6.96B | $7.17B | -9.1% |
| Total debt | $10.80B | $10.98B | $12.05B | $13.19B | -1.7% |
| Total liabilities | $16.72B | $17.80B | $19.10B | $20.30B | -6.1% |
| Retained earnings | $12.21B | $11.27B | $10.92B | $10.71B | +8.4% |
| Shareholder equity | $13.31B | $14.58B | $13.62B | $13.99B | -8.7% |
| Working capital | $1.65B | $2.26B | $2.59B | $1.74B | -26.9% |
| Net tangible assets | -$1.52B | -$1.96B | -$2.39B | -$3.32B | +22.8% |
| Shares issued | 293.41M | 293.41M | 293.41M | 293.41M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.19B | $740.87M | $732.46M | $894.33M | — | +60.8% |
| Depreciation & amortisation | $1.50B | $1.74B | $1.75B | $1.84B | — | -13.9% |
| Stock-based compensation | — | — | — | — | $0 | — |
| Change in working capital | $138.24M | $444.31M | $561.28M | -$128.07M | — | -68.9% |
| Operating cash flow | $2.68B | $2.39B | $2.63B | $2.17B | — | +12.4% |
| Capital expenditure | -$915.37M | -$699.36M | -$684.60M | -$723.99M | — | -30.9% |
| Investing cash flow | -$722.53M | -$84.94M | -$544.23M | -$734.73M | — | -750.6% |
| Share buybacks | -$585.28M | $0 | $0 | $0 | — | — |
| Dividends paid | -$422.51M | -$349.16M | -$328.62M | -$395.56M | — | -21.0% |
| Financing cash flow | -$1.40B | -$2.57B | -$1.86B | -$1.62B | — | +45.4% |
| Free cash flow | $1.77B | $1.69B | $1.94B | $1.44B | — | +4.7% |
| End cash position | $1.60B | $1.19B | $1.43B | $1.27B | — | +34.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $4.86B | $4.61B | $5.07B | $4.88B | $4.79B | — | +5.4% |
| Operating revenue | $4.86B | $4.61B | $5.07B | $4.88B | $4.79B | — | +5.4% |
| Cost of revenue | $3.55B | $3.43B | $3.68B | $3.64B | $3.58B | — | +3.4% |
| Gross profit | $1.31B | $1.18B | $1.39B | $1.24B | $1.21B | — | +11.1% |
| Research & development | $39.63M | $38.31M | $38.63M | $37.75M | $38.12M | — | +3.4% |
| Selling, general & admin | $736.01M | $748.94M | $784.62M | $705.44M | $791.98M | — | -1.7% |
| Total operating expense | $772.72M | $803.94M | $839.39M | $740.50M | $834.58M | — | -3.9% |
| Operating income | $537.27M | $375.56M | $548.98M | $501.72M | $379.78M | — | +43.1% |
| Net interest income | -$82.86M | -$78.68M | -$85.39M | -$73.94M | -$74.73M | — | -5.3% |
| Pre-tax income | $383.00M | $207.52M | $508.46M | $402.57M | $350.55M | — | +84.6% |
| Tax provision | $89.83M | $42.75M | $106.44M | $75.22M | $78.26M | — | +110.1% |
| Net income | $218.38M | $117.53M | $327.08M | $274.80M | $225.27M | — | +85.8% |
| Net income to common | $218.38M | $117.53M | $327.08M | $274.80M | $225.27M | — | +85.8% |
| Basic EPS | 0.81 | 0.43 | 1.14 | — | 0.77 | 0.52 | +88.4% |
| Diluted EPS | 0.81 | 0.43 | 1.14 | — | 0.77 | 0.52 | +88.4% |
| EBIT | $480.55M | $300.82M | $607.48M | $495.66M | $447.13M | — | +59.7% |
| EBITDA | $843.66M | $763.76M | $981.03M | $852.92M | $822.37M | — | +10.5% |
| Basic shares | 268.44M | 275.25M | 285.91M | — | 293.41M | 293.41M | -2.5% |
| Diluted shares | 268.44M | 275.25M | 285.91M | — | 293.41M | 293.41M | -2.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.06B | $1.24B | $1.58B | $1.26B | $1.72B | -14.4% |
| Cash & short-term investments | $1.45B | $1.62B | $1.82B | $1.81B | $2.19B | -10.7% |
| Accounts receivable | $3.35B | $3.58B | $3.16B | $3.24B | $3.20B | -6.5% |
| Inventory | $2.33B | $2.30B | $2.14B | $2.09B | $2.00B | +1.3% |
| Total current assets | $7.69B | $8.11B | $7.90B | $7.82B | $8.14B | -5.2% |
| Property, plant & equipment | $6.43B | $6.44B | $6.50B | $6.40B | $6.50B | -0.2% |
| Goodwill & intangibles | $15.25B | $15.10B | $14.83B | $14.84B | $14.87B | +1.0% |
| Total assets | $31.29B | $31.47B | $31.00B | $30.89B | $31.29B | -0.6% |
| Total current liabilities | $7.18B | $6.73B | $6.25B | $5.76B | $5.66B | +6.7% |
| Current debt | $1.74B | $1.80B | $1.61B | $543.25M | $1.01B | -3.0% |
| Long-term debt | $5.82B | $5.74B | $5.69B | $6.32B | $6.33B | +1.4% |
| Total debt | $10.96B | $11.03B | $10.80B | $10.47B | $11.02B | -0.6% |
| Total liabilities | $17.76B | $17.26B | $16.72B | $16.98B | $16.96B | +2.9% |
| Retained earnings | $12.09B | $12.30B | $12.21B | $11.84B | $11.29B | -1.7% |
| Shareholder equity | $12.56B | $13.24B | $13.31B | $12.95B | $13.27B | -5.2% |
| Working capital | $511.74M | $1.38B | $1.65B | $2.06B | $2.48B | -62.9% |
| Net tangible assets | -$2.69B | -$1.86B | -$1.52B | -$1.89B | -$1.60B | -44.6% |
| Shares issued | 266.11M | 293.41M | 293.41M | 293.41M | 293.41M | -9.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $293.17M | $164.76M | $402.02M | $327.34M | $272.30M | — | +77.9% |
| Depreciation & amortisation | $363.11M | $462.94M | $373.55M | $357.26M | $375.24M | — | -21.6% |
| Change in working capital | $297.16M | -$358.04M | $152.90M | $88.50M | $281.86M | — | +183.0% |
| Operating cash flow | $860.30M | $226.89M | $1.00B | $741.56M | $774.93M | — | +279.2% |
| Capital expenditure | -$240.40M | -$190.07M | -$423.01M | -$192.21M | -$154.38M | — | -26.5% |
| Investing cash flow | -$270.76M | -$169.48M | -$418.23M | -$54.01M | -$142.05M | — | -59.8% |
| Share buybacks | -$144.64M | -$347.33M | -$434.17M | -$151.12M | $0 | — | +58.4% |
| Dividends paid | — | — | $0 | $0 | — | $0 | — |
| Financing cash flow | -$769.53M | — | — | — | — | — | — |
| Free cash flow | $619.90M | $36.82M | $578.67M | $549.35M | $620.55M | — | +1,583.6% |
| End cash position | $1.06B | $1.24B | $1.60B | $1.26B | $1.72B | — | -14.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $4.96B | +1.5% |
| Next quarter | — | — | $5.10B | +0.6% |
| Current year | — | — | $19.56B | -0.4% |
| Next year | — | — | $20.22B | +3.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders28.60%
Held by institutions49.29%
Institutions holding370
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
51.44
-16.39% from price
SMA 20
50.94
+0.99% from price
SMA 50
47.46
+8.38% from price
SMA 100
45.56
-5.59% from price
SMA 200
46.25
+11.23% from price
EMA 12
51.15
-15.92% from price
EMA 26
49.91
-13.83% from price
EMA 50
48.32
-10.99% from price
RSI (14)
97.0
Overbought
MACD (12,26,9)
1.24
Hist -0.19
ATR (14)
0.00
—
Realised vol 30D
27.6%
Annualised
Bollinger upper
52.74
20, 2σ
Bollinger lower
49.14
20, 2σ
50 / 200 cross
Golden
47.46 vs 46.25
Trend bias
Above 200
+11.23%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.12
Less volatile than market
Correlation to SPY
-0.05
Largely independent
Realised vol 30D
27.6%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-25.3%
Peak to trough
Max drawdown 5Y
-65.9%
Peak to trough
ATR 14
0.00
Average true range
Beta (reported)
0.84
5Y monthly, from filing
Dividends & splits
Forward rate$1.73 / yr
Forward yield3.37%
5-year avg yield3.15%
Payout ratio44.88%
Ex-dividend dateMay 22, 2026
Next pay date—
Last split—
Split date—
Headlines
Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript
Motley Fool · 13d ago
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
Zacks · 19d ago
Fresenius Medical Care (XTRA:FME) Expands BEACON US To Build Its Case For HVHDF
Simply Wall St. · 19d ago
Fresenius Medical Care (XTRA:FME) Stock Looks Like A Bargain Despite Weak Returns
Simply Wall St. · 20d ago
Is Fresenius Medical Care (XTRA:FME) Undervalued Following Its New CEO Appointment?
Simply Wall St. · 20d ago
Fresenius Medical Care AG & Co. KGaA Q2 2026 Earnings Call Summary
Moby · 20d ago
Fresenius Medical Care AG (FMS) (Q2 2026) Earnings Call Highlights: Strong Profit Growth and ...
GuruFocus.com · 20d ago
Truist Securities Trims Price Target on Fresenius Medical Care to $25 From $26, Maintains Hold Rating
MT Newswires · 20d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.